biote Corp. cash flow to debt ratio of 32.02% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

biote Corp.'s free cash flow has decreased -22.25% from $38.81M last year to $30.18M, signaling decreasing performance

biote Corp.'s debt to equity ratio is -1.93, signaling that the company spent its equity and risk bankruptcy.

biote Corp.'s debt to equity ratio is -1.93, signaling that the company spent its equity and risk bankruptcy.

biote Corp. has a net debt to EBITDA ratio of 1.64x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

biote Corp.'s interest coverage ratio of 2.89 indicates that earnings with margin can cover interest payments on company debt

biote Corp.'s profit margin has increased (417.99%) in the last year from 1.60% to 8.29%, signaling increasing performance

biote Corp.'s short-term assets of $54.67M exceed its short-term liabilities of $44.99M

biote Corp.'s return on assets of 17.53% is higher than the 5.00% threshold, indicating efficient asset utilization

biote Corp.'s return on equity of -22.91%, is lower than 15.00%, indicating bad performance

biote Corp.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

biote Corp. had positive net income in 4.00 out of 5 years, indicating stable and consistent earnings

biote Corp. has positive free cash flow, indicating the company generates cash after capital expenditures

biote Corp. has a free cash flow yield of 38.22%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

biote Corp.'s yearly earnings has increased 756.67% since last year from $3.16M to $27.05M, signaling increasing performance

biote Corp.'s yearly revenue has decreased -2.52% since last year from $197.19M to $192.22M, signaling decreasing performance

ROIC 33.70% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

biote Corp.'s 3-year revenue CAGR of 5.23% is positive, indicating growing revenue over the past 3 years

biote Corp. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

biote Corp. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

biote Corp. is undervalued relative to its fair value price of 7.48 based on Discounted Cash Flow model

biote Corp. has an earnings yield of 28.45%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

biote Corp. is undervalued relative to its fair value price of 4.28 based on EBITDA multiple model

biote Corp. has an EV/EBITDA ratio of 4.88x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

biote Corp. is undervalued relative to its fair value price of 19.31 based on Earnings Fair Value model

biote Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

biote Corp. has negative shareholder equity; price-to-book is not meaningful and the check fails

biote Corp. has a price-to-sales ratio of 0.42x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue